08:00 , Jan 24, 2011 |  BioCentury  |  Emerging Company Profile

Arrogene: Slick chemistry from slime

Most polymer-based nanoparticles in development to deliver cancer drugs are not covalently bound to the drug. These products carry risks of toxicity because the therapeutic agent could be released early if the nanoparticle degrades before...
07:00 , Nov 4, 2010 |  BC Innovations  |  Cover Story

LAMbasting brain cancer

Approved therapies to treat brain cancer are not entirely tumor cell-specific and thus can have severe dose-limiting toxicities that decrease their effectiveness. A team of U.S. and German researchers thinks it has overcome this problem...
07:00 , Oct 14, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Transferrin receptor; laminin a4 (LAMA4); laminin b1 (LAMB1) In vitro...
08:00 , Dec 10, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Colitis Cadherin 1,...